Right Season Investments Announces Name Change to FutureGen Industries Corp.

VANCOUVER, BC / ACCESS Newswire / December 17, 2025 / Right Season Investments Corp. (TSXV:LITT) ("RightSeason" or the "Company") is pleased to announce that the Company will change its name to FutureGen Industries Corp. ("FutureGen"), effective December 22, 2025 (the "NameChange"). There will be no change to the trading symbol, and the Company's common shares will continue to trade under "LITT" on the TSX Venture Exchange.

The CUSIP number assigned to the Company's shares following the Name Change to FutureGen Industries Corp. is 36118G107 (ISIN: CA36118G1072). No action is required by shareholders; all existing share and warrant certificates remain valid and unaffected. Any questions regarding the Name Change can be directed to the Company's Investor Relations by email at investor@rightseasoninvestmentscorp.com or by telephone at 1-833-383-9900.

About Right Season Investments Corp.

Right Season Investments Corp. is a Canadian venture capital, investment and advisory firm that strives to actively drive innovation and accelerate growth for its shareholders. Right Season invests capital into private and public companies that offer excellent growth opportunities.

Contact:

Kristian Thorlund, CEO
Tel: 1 833 383 9900
Email: investor@rightseasoninvestmentscorp.com

Cautionary and Forward-Looking Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of the Company's management on the date the statements are made. The Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates, or opinions, or other factors, should change, except as required by law.

SOURCE: Right Seasons Investments



View the original press release on ACCESS Newswire

News Provided by ACCESS Newswire via QuoteMedia

LITT:CC
The Conversation (0)
Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Q4 Fiscal 2025 Highlights Revenue of $2.3 million, a 29.0% increase over Q3 2025 Gross profit of $1.4 million, compared to a gross profit of $0.8 million in Q3 2025 Cash position of $0.5 million as of August 31, 2025 Subsequent to Quarter End On April 18, 2026, President Donald Trump signed an... Keep Reading...
The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

Brisbane, Australia - The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, is pleased to announce the execution of an Exclusive Distribution Agreement with a... Keep Reading...
Gloved hand holds a cluster of brown mushrooms growing from a gray substrate block.

Psychedelics Market Trends: H1 2026 Review and Forecast

The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped... Keep Reading...
A pill bottle with US flag and coloured pills.

Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets

The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
Dried mushrooms surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, but Risks Remain

On April 18, US President Donald Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments for Serious Mental Illness, an executive order (EO) to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...

Interactive Chart

Latest Press Releases

Related News